Saturday 17 October 2026
Export CURX’s income statement to Excel — free account
Curanex Pharmaceuticals Inc
CURX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 4,671.4% and free cash flow fell 272.3%, each against the same quarter a year earlier.
4.62
0.21
−4.35%
Follow CURX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
45.95 | 62.89 | 81.95 | 77.52 |
+5 more quarters Free account |
Net Debt/EBITDA |
0.89 | 1.28 | 1.63 | 6.23 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.33 | 0.30 | 0.28 | 9.63 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | — | — | (232.02) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | — | |
Free Cash Flow per Share |
(0.76) | (0.67) | (0.67) | (7.18) | |
Cash per Share |
2.07 | 2.84 | 3.90 | 4.56 | |
Shareholders Equity per Share |
3.38 | 5.70 | 8.80 | 11.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.38 | 5.70 | 8.80 | 11.17 | |
Free Cash Flow |
(1.08) | (0.95) | (0.86) | (9.19) | |
Working Capital |
4.69 | 7.97 | 11.09 | 14.23 | |
Net Current Asset Value |
4.51 | 7.76 | 10.87 | 14.23 | |
| Other line items | |||||
Quick Ratio |
28.17 | 31.22 | 36.30 | 31.35 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.76) | (0.67) | (0.67) | (7.18) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.00 | 0.01 | — | — | |
Average Assets |
2.93 | 4.21 | 5.79 | 7.24 | |
Average Common Equity |
2.55 | 4.29 | — | — |
Columns are period end dates